Department of Immunology, School of Basic Medical Sciences, Peking University, Beijing, China.
Division of Infection and Immunity, Department of Immunology, UCL (University College London), London, UK.
Adv Exp Med Biol. 2024;1445:73-88. doi: 10.1007/978-981-97-0511-5_6.
Immunoglobulin (Ig) has been widely acknowledged to be produced solely by B-lineage cells. However, growing evidence has demonstrated the expression of Ig in an array of cancer cells, as well as normal cells including epithelial cells, epidermal cells, mesangial cells, monocytes, and neutrophils. Ig has even been found to be expressed in non-B cells at immune-privileged sites such as neurons and spermatogenic cells. Despite these non-B cell-derived Igs (non-B-Igs) sharing the same symmetric structures with conventional Igs (B-Igs), further studies have revealed unique characteristics of non-B-Ig, such as restricted variable region and aberrant glycosylation. Moreover, non-B-Ig exhibits properties of promoting malignant behaviours of cancer cells, therefore it could be utilised in the clinic as a potential therapeutic biomarker or target. The elucidation of the generation and regulation of non-B-Ig will certainly broaden our understanding of immunology.
免疫球蛋白 (Ig) 被广泛认为仅由 B 细胞谱系细胞产生。然而,越来越多的证据表明 Ig 在一系列癌细胞以及包括上皮细胞、表皮细胞、肾小球系膜细胞、单核细胞和中性粒细胞在内的正常细胞中表达。Ig 甚至在免疫豁免部位如神经元和精原细胞中被发现存在于非 B 细胞中。尽管这些非 B 细胞来源的 Ig(非 B-Ig)与传统 Ig(B-Ig)具有相同的对称结构,但进一步的研究揭示了非 B-Ig 的独特特征,例如受限的可变区和异常糖基化。此外,非 B-Ig 表现出促进癌细胞恶性行为的特性,因此它可以在临床上用作潜在的治疗性生物标志物或靶标。阐明非 B-Ig 的产生和调节将肯定拓宽我们对免疫学的理解。